Non-clinical programs

In addition to the development of BIT225, Biotron has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.

Viroporins are encoded by many viruses and are essential for pH-dependent viral uncoating and/or assembly of infectious virus. Their role in viral pathogenesis supports their essential role in the virus life cycle, making viroporins ideal targets for therapeutic intervention.

Biotron’s unique approach to designing, screening, and developing small molecules that work against viroporin proteins enables the targeting of a wide range of viral disease; examples include:

  • Influenza (in particular resistant strains)
  • Dengue virus
  • Zika Virus
  • Ebola and SARs

Clinical studies with BIT225 have demonstrated the robustness of Biotron’s approach providing strong validation of safety & efficacy of targeting viroporins.